Pablo G. Legorreta - 08 May 2025 Form 4 Insider Report for Royalty Pharma plc (RPRX)

Role: CEO, Chairman of the Board, Director
Signature: /s/ Sean Weisberg, as Attorney-in-Fact for Pablo G. Legorreta
Issuer symbol: RPRX
Transactions as of: 08 May 2025
Net transactions value: $0
Form type: 4
Filing time: 09 May 2025, 17:18:28 UTC
Previous filing: 06 Feb 2025
Next filing: 14 May 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Legorreta Pablo G.	CEO, Chairman of the Board, Director	C/O ROYALTY PHARMA PLC, 110 E. 59TH STREET, NEW YORK	/s/ Sean Weisberg, as Attorney-in-Fact for Pablo G. Legorreta	09 May 2025	0001507678

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	RPRX	Class A Ordinary Shares	Award	$0	+288,352	+452%	$0.000000	352,147	08 May 2025	Direct	F1
holding	RPRX	Class A Ordinary Shares						460,139	08 May 2025	By Legorreta Investments LLC
holding	RPRX	Class A Ordinary Shares						123,310	08 May 2025	By IRRA
holding	RPRX	Class A Ordinary Shares						118,500	08 May 2025	By SEP/IRA
holding	RPRX	Class A Ordinary Shares						1,040,410	08 May 2025	By Legorreta Children 2002 Trust
holding	RPRX	Class A Ordinary Shares						901,590	08 May 2025	By GST-Exempt Legorreta 2012 Family Trust
holding	RPRX	Class A Ordinary Shares						41,306	08 May 2025	By GST-Exempt Legorreta 2020 Family Trust
holding	RPRX	Class A Ordinary Shares						6,930	08 May 2025	By Spouse
holding	RPRX	Class A Ordinary Shares						292,190	08 May 2025	By Tata MC 35 Ltd.
holding	RPRX	Class A Ordinary Shares						10,000	08 May 2025	By Son
holding	RPRX	Class A Ordinary Shares						10,000	08 May 2025	By Daughter
holding	RPRX	Class A Ordinary Shares						600,000	08 May 2025	By Legorreta 2023 SR Trust

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Reflects the exempt acquisition by the Reporting Person pursuant to Rule 16b-3 of Class A Ordinary Shares of the Issuer in connection with the settlement of Equity Performance Awards.